论文部分内容阅读
美沙拉嗪缓释剂可有效地治疗轻度和中度活动性炎症性肠疾病,长期服用可在一定程度上防止缓解期炎症性肠疾病的复发。其不良反应轻微,安全性明显优于柳氮磺胺吡啶,因此可望取代后者而广泛地应用于临床
The mesalazine sustained-release agent can effectively treat mild and moderate active inflammatory bowel diseases, and long-term administration can prevent the recurrence of inflammatory bowel diseases in the remission period to a certain extent. Its minor adverse reactions, safety significantly superior to sulfasalazine, it is expected to replace the latter and widely used in clinical